Aditoprim is a long-acting, selective, reversible inhibitor of dihydrofolate reductase with application as a broad-spectrum antibacterial agent in animals. Aditoprim is low toxic and not mutagenic.Many gram-positive and gram-negative bacteria are highly susceptible or susceptible to Aditoprim, especially Salmonella and Streptococcus, while H. parasuis and Klebsiella were moderately susceptible to Aditoprim. Phase II clinical study of Aditoprim on therapeutic effect on swine streptococcosis has demonstrated that Aditoprim is as active as compound sulfadiazine, which provides reasonable theoretical foundation for the clinical application of Aditoprim.

Enoxamast (PRH-836-EA) is a N-(4-substituted-thiazolyl)oxamic acid derivative with antiallergic activity.

Nifuroquine is an antibacterial agent, used in the treatment of bovine mastitis.

Butaprost, a structural analog of PGE2, is a selective agonist for the EP2 receptor subtype. EP2 receptors are expressed on human neutrophils and on respiratory, vascular, and uterine smooth muscle. Butaprost binds with about 1/10 the affinity of PGE2 to the recombinant murine EP2 receptor and does not bind appreciably to the other murine EP receptors or the DP, TP, FP, and IP receptors. Butaprost has frequently been used to pharmacologically define the EP receptor expression profile of various human and animal tissues and cells. Butaprost effectively reduces the subconjunctival scarring response. Given the significance of wound healing modulation in blebs, butaprost's inhibitory effect on subconjunctival Tenon's fibroblasts may be beneficial in managing postoperative scarring in glaucoma surgery.

Tamolarizine (also known as NC-1100), an organic Ca2+ channel blocker, was studied in clinical trials phase II in patients with neurological disorders. However, these studies were discontinued. In addition, experiments on rodents have shown that tamolarizine treatment protected the hippocampus from ischemic brain damage and ameliorated place learning impairment. Tamolarizine was also able to reverse the multidrug-resistance phenotype in human leukemia K562 cells through direct interaction with P-glycoprotein.

Valdipromide is an antidepressant.

Setipafant [BN 50727], triazolothienodiazepine, is a synthetic platelet activating factor antagonist that was under development with Beaufour-Ipsen for the treatment of diarrhoea, inflammatory bowel diseases, peptic ulcer and ulcerative colitis. The research has been discontinued.

Shionogi developed S 777469 as a selective cannabinoid 2 receptor agonist for the atopic dermatitis treatment. This drug successfully completed phase II clinical trial, where was evaluate its safety and efficacy in patients with atopic dermatitis. However, information about the further development of S 777469 is not available.

Icomucret (15(S)-HETE) is an hydroxyeicosatetraenoic acid developed by Alcon Research, Ltd for treatment Ophthalmic Disorders. In vitro Icomucret has been shown to inhibit LTB4 formation, 12-HETE formation and specifically inhibits the neutrophil chemotactic effect of LTB4. The inhibition of LTB4 formation is probably due to modulation of the 5- lipoxygenase (LO) because no changes in PGE2 formation have been determined. In vivo, Icomucret inhibits LTB4-induced erythema and edema, and reduces LTB4 in the synovial fluid of carragheenan-induced experimental arthritis in dogs. Icomucret has also some immunomodulatory effects. It inhibits the mixed lymphocyte reaction, induces generation of murine cytotoxic suppressor T cells, and it decreases interferon production by murine lymphoma cells. Furthermore, IL-4 and IL-13 have recently been shown to be potent activators of the 15-LO in mononuclear cells. Icomucret induces the secretion of membrane-bound mucins from human conjunctival and corneal epithelial cells. Icomucret was evaluated in clinical trials for Dry Eye Syndrome treatment. However from 2007 no future development reported, and Icomucret development sims to be discontinued.

Efletirizine is histamine H1 receptor antagonist. Restricted to topical use. It was under investigation in Phase III (in Europe) clinical studies for the treatment of allergic rhinitis and chronic idiopathic urticarial. Research was discontinued in 2005 due to limited clinical efficacy and safety data. Efletirizine also reduced ocular itching.